 |
|
Technique eradicates problems in most patients with Barrett's esophagus
May 28, 2009A procedure that uses heat generated by radio waves to treat Barrett's esophagus, a condition caused by acid reflux (severe heartburn), can eliminate signs of the potentially cancer-causing disorder and reduce the risk that the disease will progress.
Findings from the first multicenter trial of the procedure, called radiofrequency ablation, could mean patients have an alternative to surgery for treating Barrett's esophagus. The procedure uses a scope inserted through the mouth to destroy the abnormal tissue. The investigators report their findings in the May 28 issue of the New England Journal of Medicine.
"Patients with Barrett's esophagus can go on to develop esophageal cancer," says Steven A. Edmundowicz, M.D., lead investigator at the study site at Washington University School of Medicine in St. Louis. "Cancer of the esophagus usually is deadly. Less than 15 percent of patients with esophageal adenocarcinoma survive for five years, and in those with advanced Barrett's esophagus, the risk that the condition will advance to become cancer is about 6 percent per year."
In Barrett's esophagus, part of the lining of the esophagus is replaced with cells that resemble intestinal cells. As the condition progresses, these cells become increasingly disordered. Long-standing acid reflux disease is common in those who develop Barrett's esophagus, which affects about 1 percent of adults in the United States.
A total of 127 patients at 19 sites took part in the study, which used endoscopes to diagnose the disease and then to deliver radiofrequency ablation to the abnormal lining of the esophagus. The technique heats the abnormal tissue to destroy it while leaving the deeper layers of the esophagus undamaged.
All patients in the study had the disordered, cellular growth called dysplasia associated with more advanced Barrett's esophagus. Patients were classified as having either low-grade dysplasia or high-grade dysplasia. Regardless of how they were classified for the study, patients received the anti-reflux medication esomeprazole (Nexium), to keep their reflux disease in check as much as possible.
Led by Nicholas J. Shaheen, M.D., at the University of North Carolina at Chapel Hill, the investigators at the various study sites randomly selected patients to either receive radiofrequency ablation or to undergo a sham procedure in which endoscopes were inserted through the mouth and the lining of the esophagus was examined, but no radio waves were delivered.
Two patients received the actual treatment for every one who got a sham procedure. Those who received the ablation treatment could get up to four treatments during the 12 months of the study. Following the study period, those who had not received ablation therapy were given the option of getting the treatment.
In the patients who had the treatment, dysplasia disappeared in just over 90 percent of patients with low-grade disease and in more than 80 percent of those with high-grade disease compared to about 23 percent of the low-grade patients and 19 percent of the high-grade patients who had sham procedures rather than the ablation therapy. In 78 percent of treated patients, not only did dysplasia disappear, but all the abnormal intestinal-type cells were eliminated as well.
"During the 12-month study period, we detected fewer cancers in the ablation group than in the control group," says Edmundowicz, a professor of medicine in the Division of Gastroenterology. "But because cancers occurred in a total of only five study patients, the numbers are not as powerful regarding cancer as they are regarding eradication of Barrett's esophagus."
The risk of progressing from Barrett's esophagus to esophageal cancer is approximately 1 percent for those with low-grade dysplasia and 6 percent for those with high-grade disease.
"From these short term results, it appears we may have another useful tool in our treatment arsenal," says Edmundowicz, who is a staff physician at Barnes-Jewish Hospital and a gastroenterologist at the Siteman Cancer Center. "Additional follow-up will be necessary to demonstrate the true effectiveness of radiofrequency ablation in preventing esophageal cancer in patients with Barrett's esophagus. "
Most study subjects tolerated the treatments very well, he says. "The one side effect that most ablation patients experienced was soreness in the chest following therapy, this was easily managed with medications, and they were less sore than if they had surgery, which has been the primary treatment option," he says.
The surgical option is offered to patients with Barrett's esophagus found to have severe dysplasia or cancer. The type of surgery varies, but it usually involves removing most of the esophagus, pulling a portion of the stomach up into the chest and attaching it to what remains of the esophagus.
The study was supported by BARRX Medical, which manufactures the ablation device. All patients in the study also received the anti-reflux drug. Edmundowicz has received lecture support from BARRX Medical. Other disclosures for study investigators are listed in the article in the New England Journal of Medicine.
Washington University School of Medicine
In Barrett's esophagus, part of the lining of the esophagus is replaced with cells that resemble intestinal cells. As the condition progresses, these cells become increasingly disordered. Long-standing acid reflux disease is common in those who develop Barrett's esophagus, which affects about 1 percent of adults in the United States.
A total of 127 patients at 19 sites took part in the study, which used endoscopes to diagnose the disease and then to deliver radiofrequency ablation to the abnormal lining of the esophagus. The technique heats the abnormal tissue to destroy it while leaving the deeper layers of the esophagus undamaged.
All patients in the study had the disordered, cellular growth called dysplasia associated with more advanced Barrett's esophagus. Patients were classified as having either low-grade dysplasia or high-grade dysplasia. Regardless of how they were classified for the study, patients received the anti-reflux medication esomeprazole (Nexium), to keep their reflux disease in check as much as possible.
Led by Nicholas J. Shaheen, M.D., at the University of North Carolina at Chapel Hill, the investigators at the various study sites randomly selected patients to either receive radiofrequency ablation or to undergo a sham procedure in which endoscopes were inserted through the mouth and the lining of the esophagus was examined, but no radio waves were delivered.
Two patients received the actual treatment for every one who got a sham procedure. Those who received the ablation treatment could get up to four treatments during the 12 months of the study. Following the study period, those who had not received ablation therapy were given the option of getting the treatment.
In the patients who had the treatment, dysplasia disappeared in just over 90 percent of patients with low-grade disease and in more than 80 percent of those with high-grade disease compared to about 23 percent of the low-grade patients and 19 percent of the high-grade patients who had sham procedures rather than the ablation therapy. In 78 percent of treated patients, not only did dysplasia disappear, but all the abnormal intestinal-type cells were eliminated as well.
"During the 12-month study period, we detected fewer cancers in the ablation group than in the control group," says Edmundowicz, a professor of medicine in the Division of Gastroenterology. "But because cancers occurred in a total of only five study patients, the numbers are not as powerful regarding cancer as they are regarding eradication of Barrett's esophagus."
The risk of progressing from Barrett's esophagus to esophageal cancer is approximately 1 percent for those with low-grade dysplasia and 6 percent for those with high-grade disease.
"From these short term results, it appears we may have another useful tool in our treatment arsenal," says Edmundowicz, who is a staff physician at Barnes-Jewish Hospital and a gastroenterologist at the Siteman Cancer Center. "Additional follow-up will be necessary to demonstrate the true effectiveness of radiofrequency ablation in preventing esophageal cancer in patients with Barrett's esophagus. "
Most study subjects tolerated the treatments very well, he says. "The one side effect that most ablation patients experienced was soreness in the chest following therapy, this was easily managed with medications, and they were less sore than if they had surgery, which has been the primary treatment option," he says.
The surgical option is offered to patients with Barrett's esophagus found to have severe dysplasia or cancer. The type of surgery varies, but it usually involves removing most of the esophagus, pulling a portion of the stomach up into the chest and attaching it to what remains of the esophagus.
The study was supported by BARRX Medical, which manufactures the ablation device. All patients in the study also received the anti-reflux drug. Edmundowicz has received lecture support from BARRX Medical. Other disclosures for study investigators are listed in the article in the New England Journal of Medicine.
Washington University School of Medicine
Esophagus Current Events and Esophagus News RSSReflux esophagitis due to immune reaction, not acute acid burn, UT Southwestern researchers report
Contrary to current thinking, a condition called gastroesophageal reflux disease (GERD) might not develop as a direct result of acidic digestive juices burning the esophagus, UT Southwestern Medical Center researchers have found in an animal study.
African-Americans with colorectal cancer have poorer outcomes, lower survival rates
New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans.
California Academy of Sciences becomes first aquarium in US to breed dwarf cuttlefish
Anchored to an algae-covered rock in a 120-gallon tank at the California Academy of Sciences' Steinhart Aquarium, a cluster of inky-colored cuttlefish eggs is beginning to swell-evidence of success for the Academy's new captive breeding program for dwarf cuttlefish, Sepia bandensis.
Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer
Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results.
Surgeons at Boston Medical Center offering new procedure for acid reflux/GERD
Boston Medical Center (BMC) surgeons are now offering patients an incisionless alternative to laparoscopic and traditional surgery for treatment of acid reflux or GERD.
Barrett's esophagus patients have same survival rates as general population
New Mayo Clinic research has found that survival rates of patients with Barrett's esophagus, which can be a precursor for esophageal cancer, are no different than the survival rates for the general population.
UF scientists discover new explanation for controversial old patient-care technique
You might not know what it's called, but if you've had general anesthesia before surgery, especially after an accident, it is likely you have received Sellick's maneuver.
Many patients with sleep apnea also suffer from GI tract conditions
Patients who suffer from obstructive sleep apnea (OSA) also tend to have additional gastrointestinal (GI) tract conditions, such as gastric reflux and hiatal hernia, which form at the opening in your diaphragm where your food pipe (esophagus) joins your stomach.
Artificial intelligence helps diagnose cardiac infections
Mayo Clinic researchers say that "teachable software" designed to mimic the human brain may help them diagnose cardiac infections without an invasive exam.
GERD negatively impacts sleep quality, results in considerable economic burden
There has been much debate about the relationship between gastroesophageal reflux disease (GERD) and sleep.
More Esophagus Current Events and Esophagus News Articles
 |
Horsemen of the Esophagus: Competitive Eating and the Big Fat American Dream by Jason Fagone (Author) “To be up on stage, shoving food in your face, beats everyday existence for most people.” —David “Coondog” O’Karma, competitive eater “Hungry” Charles Hardy. Ed “Cookie” Jarvis. Sonya “The Black Widow” Thomas. Joey “Jaws” Chestnut. Will such names one day be looked back upon as the pioneers of a new manifestation of the irrepressible American appetite for competition, money, fame, and self-transformation? They will if the promoters of the newly emerging sport of competitive eating have their way. In Horsemen of the Esophagus, Jason Fagone reports on the year he spent in the belly of this awakening beast. Fagone’s trek takes him to 27 eating contests on two continents, from the World Grilled Cheese Eating Championship in Venice Beach, California,... |
|
The Esophagus by Donald O Castell (Editor), Joel E Richter (Editor) Medical Univ. of South Carolina, Charleston. Brandon/Hill Medical List selection (#209). Provides complete and current information on the diagnosis and treatment of all esophageal disorders. Addresses both medical and surgical therapies and discusses reflux disease, trauma, hernias, diverticula, and Barrett's esophagus. Previous edition: c1999. Esophagus--Diseases. | |
 |
Problems of the Esophagus: GERD and Barrett's Esophagus Studies suggest that more than 15 million Americans suffer from heartburn everyday and spend millions of dollars in search of relief from this condition. Dr Lauren Gerson discusses heartburn and other problems of the esophagus, including Barrett's Esophagus, in this talk. She focuses on the causes and some of the solutions for these problems as indicated by the latest research, including studies conducted at Stanford. |
 |
3B Scientific Illnesses of the Esophagus by 3B Scientific |
 |
BEEF ESOPHAGUS 6"-25 ea by KNine Kountry BEEF ESOPHAGUS STRIPS 6 INCHES LONG WITH WIDTHS FROM 1.5 TO 3 INCHES. |
 |
Diseases of the Esophagus Model-K18 by Anatomical Chart Company |
 |
Barrett's Esophagus a Multistage Model of Human Carcinogenesis (NCME Video 669) Also With: Network For Continuing Medical Education (Primary Contributor), Douglas S. Levine (Primary Contributor) The past two decades have seen a dramatic rise in the incidence of esophageal adenocarcinomas. The precursor of such cancers appears to be Barrett's esophagus, a complication of chronic gastroesophageal reflux. Dr. Levine performs endoscopic biopsy surveillance to diagnose this condition and demonstrates the latest techniques for measuring proliferative and genomic abnormalities. |
|
TNM Staging and Anatomical Reference: Pharynx, Esophagus, Lung, Breast, Ovary, Urinary Bladder, Prostate, Colon and Rectum by 1999 Doctors+Designers/Approved Patient-Centered Health Education/Bristol-Myers Squibb Oncology | |
|
Esophagus 13 tracks | |
 |
Treatment Options For Barrett's Esophagus Lifeline Audio Books (Primary Contributor) |
| © 2009 BrightSurf.com |